Based on its important physical and pathological function, the androgen receptor (AR) is regarded as a significant drug target. In this report, the authors describe a novel strategy of protein chip technology to screen agonists and antagonists of AR. First, the AR ligand binding domain (AR-LBD) was expressed in Escherichia coli, purified, and then immobilized on a silanepolysaccharide surface of a protein chip. Second, the affinities of methyltestosterone (MT) and fluorescent-labeled testosterone for the AR-LBD protein chip were determined. Third, a converse strategy of the protein chip was tested to evaluate its reliability as a drug screening method. Fourth, a 10,067-compound library was screened to find new ligands of AR. From the results, the K d of testosterone and the IC 50 of MT are consistent with the literature (0.61 vs. 0.49 nM 2.88 vs. 3.90 nM, respectively). The Z′ factor of the high-throughput screening (HTS) method was 0.76, which meets the requirement of drug screening (>0.4). Finally, 3 active ligands of AR were identified with their IC 50 values of 3.63, 2.19, and 1.71 μM, respectively. In summary, the novel strategy of the AR-LBD protein chip was suitable for HTS at the molecular level. (Journal of Biomolecular Screening 2008:276-284) 
INTRODUCTION
T HE ANDROGEN RECEPTOR (AR) IS A MEMBER of the nuclear receptor superfamily, which includes glucocorticoid, estrogen, progesterone, retinoic acid, and thyroid receptors. 1 The AR distributes in a variety of tissues, including sweat glands, hair follicles, cardiac muscles, vascular and gastrointestinal smooth muscles, and thyroid follicular and adrenal cortical cells. 2 The AR has important effects throughout life, including the obvious effects on pubertal development, the physiologic dysregulation that contributes to male pattern baldness, the genesis of prostatic hyperplasia, and prostate cancer later in life. 3 According to statistics from the American Cancer Society for 2007, 1 in every 6 men in the United States has a lifetime chance of being diagnosed with prostate cancer.
Detailed molecular genetic analyses and functional domain studies have markedly expanded our understanding of the AR molecular physiology. The AR gene is located on chromosome Xq11-12 and spans 90 kb of DNA. 4, 5 The genomic organization of AR is conserved throughout mammalian evolution from rodents to humans. 6 The AR protein, with 110 kDa, is composed of a variable NH 2 -terminal domain, a DNA binding domain, a hinge domain, and a ligand binding domain (LBD). In the cytoplasm, AR can be phosphorylated at a number of sites in response to the binding of the agonist but not antagonists. 7 The activated AR changes its stereo conformation, translocates to the nucleus, and contributes to transcriptional regulation. 8 Based on its important physical and pathological function, the AR is regarded as a significant drug target. More effective androgen drugs are needed for clinical use. In this report, we describe a novel strategy of protein chip technology to screen agonists and antagonists of androgen receptors.
As a new high-throughput screening (HTS) technology, the protein chip has been widely used in proteomic analysis, diseases diagnosis, pathological research, and drug mechanism studies. [9] [10] [11] The advantages of the protein chip over conventional methods, such as the enzyme-linked immunosorbent assay (ELISA) and the radioactive binding assay, are that they have no radioactive hazard, perform quickly, and use fewer samples. 12, 13 The protein chip is thought to be 10 to 100 times faster than conventional methods. Fang et al. 14 verified the binding assay on the chip by membrane receptors. We have used a multiple-receptor chip to detect prohibited drugs in athletes' urine 15 and an enzyme chip to screen elastase inhibitors. 16 However, to our knowledge, there are no reports about the application of receptor chips in high-throughput drug discovery. In this study, we first prepared the AR-LBD protein and a silane-polysaccharide surface to fabricate the protein chip. Second, we validated the feasibility of the receptor binding assay on the chip. Last, a novel strategy of the protein chip was designed to screen a 10,067-compound library to find new agonists and antagonists of AR.
MATERIALS AND METHODS

Materials
Escherichia coli BL21 (DE3) and vector pET32a were purchased from Novagen Company (San Diego, CA). E. coli TG1 was conserved in the National Centre of Pharmaceutical Screening. Male Wistar rats (280-300 g) were supplied by the Institute of Animals, Chinese Academy of Medical Science. Vector pGEM-T was bought from Promega (Madison, WI). Restriction enzymes XhoI and BamHI, alkaline phosphatase, reverse transcriptase (M-MLV), Taq, RNAase, and isopropyl-P-p-thiogalactopyranoside (IPTG) were bought from Takara (Otsu, Shiga, Japan). Ni-NTA (His-tag affinity sepharose), Trizol, and fluorescein isothiocyanate-labeled testosterone (FITC-T) were obtained from Invitrogen (Carlsbad, CA). 3-Aminopropyltrimethoxysilane (APTS) was bought from Sigma-Aldrich (St. Louis, MO). Androgen receptor antibody was ordered from Santa Cruz (Santa Cruz, CA). Methyltestosterone (MT) was obtained from the Chinese National Institute for the Control of Pharmaceutical and Biological Products. All other reagents were of analytical or guaranteed reagent grade.
cDNA cloning and recombinant plasmids construction
When rats were castrated, they were given 25 mg cyproterone. After 3 days, the ventral prostate of the rat was separated to extract total RNA using the Trizol reagent. The AR-LBD cDNA was prepared by reverse transcriptase PCR (RT-PCR). The reverse transcriptional primer and 2 PCR primers were designed as follows: p1 (5′-CAAGGTGGGTTTGGGTATTAGGGTTTCC-3′), p2 (5′-GGGATCCACTCTGGGAGCTCGTAAGCTGAAGAAA-3′), and p3 (5′-CCTCGAGTCACTGTGTGTGGAAATAGAT-GGGC-3′). Amplicons were cloned into a pGEM-T vector and amplified in E. coli strain TG1. After a sequence test, the AR-LBD cDNA was cloned into a pET32a, resulting in the recombinant plasmid pET32a-AR. Then, 1% agarose gel electrophoresis and DNA sequence analysis were used to identify the construction.
Expression of the recombinant AR-LBD in E. coli BL21 (DE3)
When the bacteria grew to an optical density of 0.8 to 1.3 at 37 °C, 1 mM IPTG was added to induce protein expression. After an additional incubation for 12 h at 16 °C, the bacteria were harvested by centrifugation at 5000 g for 10 min. The bacterial pellets were resuspended in 10 mL ice-cold TEGM buffer (10 mM Tris-HCl, 1 mM EDTA, 10% glycerol, 10 mM sodium molybate, pH 7.4) containing phenylmethylsulfonyl fluoride (PMSF; 100 μg/mL), leupeptin (1 μg/mL), and pepstatin (1 μg/mL). This suspension was subjected to sonication using ten 10-s bursts on ice by a SONPULS 2070 (Bandelin, Berlin, Germany). The crude soluble receptors were prepared by ultracentrifugation at 10,000 g for 30 min at 4 °C.
Purification of the recombinant AR-LBD
The recombinant AR-LBD protein was purified using Ni-NTA as described by the manufacturer. Then, 10 mL sterile water was used to balance the purification column, and 20 mL native binding buffer (50 mM NaH 2 PO 4 , 0.5 mM NaCl, pH 8.0) was loaded to balance the column again. In the meantime, a UV monitor was calibrated to set up the baseline and maximum. The lysate passed through the purification column in 30 min. Then, 0.1 M imidazole native washing buffer was used to elute the protein. Different fractions were collected based on the UV monitor curve, and 1 mL of each fraction was kept for sodium dodecyl sulfatepolyacrylamide gel electrophoresis (SDS-PAGE) and Western blot analysis. Finally, the high concentration of imidazole was removed by dialysis. The AR-LBD protein can be lyophilized and stored at -80 °C.
Western blot identification
Proteins were analyzed using 12.5% SDS-PAGE and transferred to a polyvinylidene difluoride (PVDF) membrane (Schleicher & Schuell, Dassel, Germany) at 9 voltages for 60 min. After being blocked with 5% skimmed milk, the membrane was incubated with the primary AR antibody overnight at room temperature and then incubated with the second antibody for 1 h. The membrane was washed and developed using the chemiluminescence system (ECL, Amersham Bioscience, Cardiff, UK).
Protein chip surface activation
A 2.0-mL aliquot of 1% agarose in purified water (containing 10 mM NaIO 4 ) was heated to 70 °C and poured over an APTSmodified slide surface 17 per slide. After agarose gelling, slides were dipped in water for 4 h and then dried at 37 °C for 6 h. The dried agarose-coated slides were either used for protein immobilization immediately or stored at 4 °C. 18
Measurement of the binding ability of the AR chip
Protein arrays fabrication. The AR-LBD proteins (750 nM) were printed 19 using a quill-pin printer (pin-based spotting printer Dy-2003, Institute of Electrical Engineering, Chinese Academy of Sciences) with 50 nL per spot, which has a 100-μm spot diameter, 500-μm spot distance, and 60-ms contact time of pins on the surface. The arrays can be stored at 4 °C in a desiccator filled with nitrogen for several months.
Determining the affinity of AR-LBD protein for FITC-T.
Twelve arrays were set up on a slide using AR-LBD, with triplicate spots in each array. The arrays were separated by a removable grid (National Engineering Research Center for Beijing Biochip Technology, China). Duplicate arrays were chosen with one being used for total binding and the other for nonspecific binding at each concentration of FITC-T (0.2, 0.5, 1.28, 3.2, 8, 20 nM). The same 30-μL binding buffer (50 mM Tris-HCl [pH 7.4], 10 mM MgCl 2 , 1 mM EDTA, and 0.1% bovine serum albumin [BSA]) was added to all of the arrays. In addition, 1 μM MT was used to block specific binding and was added to the nonspecific arrays. After being incubated in a humid chamber (National Engineering Research Center for Beijing Biochip Technology, China) at 37 °C for 20 min, slides were washed 3 times by PBST (phosphate-buffered saline [PBS] with 0.05% Tween-20) to remove unbound FITC-T and scanned using a 488-nm laser for excitation and a 520-nm filter for collection of fluorescence by Scan-3 (Institute of Optics and Electronics, Chinese Academy of Sciences, China).
Competitive binding assay of MT using a converse strategy of protein chip
An AR-LBD layer (750 nM) was coated uniformly on the prepared slide. The absorbance was enhanced for 30 min at 4 °C. The unbound protein was washed by PBST. MT at concentrations from 10 -6 to 10 -11 M was printed on the protein chip to produce 3 × 9 compound arrays using the printing robot. The printing buffer contains 50 mM Tris-HCl (pH 7.4), 10 mM MgCl 2 , 1 mM EDTA, 0.1% BSA, and 5% glycerol. Because glycerol was added in the printing solution, samples spots can form gibbous globelets by absorbing water in the humid chamber ( Fig. 1) . After a 15-min incubation, 10 nM FITC-T in the binding buffer was added to the arrays. The chip underwent the competitive binding reaction in a humid reaction chamber for another 15 min at 27 °C. The subsequent steps were the same as above.
Reliability evaluation of the converse protein chip
A 5 × 8 compound array was set up on an AR-LBD chip. This array contained 3 control groups, including a negative control (the printing buffer), 0.1% DMSO control, and a positive MT control (0.03, 0.3, and 1 μM). The subsequent steps were the same as the competitive binding assay.
High-throughput compound screening using the converse AR-LBD chip
A protein chip can be formatted into 2 blocks on a 2 × 2.4-cm area of each glass slide. Each block contains 21 × 10 compound arrays. The array density was 210 spots/cm 2 . Each chemical sample was applied as a single spot, and 420 chemical samples can be loaded and screened in each slide, including the control samples. A positive control (1 μM MT) and a negative control were set up in the 4 corners of a block. The candidates from the primary screening underwent further selection. Each candidate compound from the primary screening was tested to calculate its IC 50 . The operation was the same as the competitive binding assay.
Statistical analyses
Data collected from the protein chip were initially gray-scale pictures. The array analysis software (ImageAnalyer 1.0, Institute of Optics and Electronics, Chinese Academy of Sciences) automatically merges rainbow colors from blue, red, to white to easily symbolize the increase of relative fluorescence units (RFUs). All values used in this article were with the local backgrounds auto-subtracted by the software. In the converse competitive binding assay, the maps were inverted to show the compounds' binding abilities directly. When the binding affinity of the AR-LBD chip for FITC-T was measured, the specific binding values equaled the difference between the total binding values and the nonspecific binding values. The Scatchard plot was used to obtain K d (dissociate constant, a measure of the affinity of a drug for a receptor). In the competitive experiment, data were plotted on a log rather than a linear plot. GraphPad Prism 4.0 (San Diego, CA) was used for graphic presentation and statistical analyses. Precision parameters involving coefficient of variation (CV) and Z′ factor were calculated according to Zhang 
RESULTS
Preparation of the AR-LBD protein
The expression vector pET32a/AR was transformed into BL21. SDS-PAGE was used to analyze the expression products. After being purified by Ni-NTA, the target protein, fused with a His-tag, was collected and analyzed by protein electrophoresis with silver staining. Its MW was about 54.4 kDa (Fig. 2) . The UV monitor map showed a specific absorbance peak of AR-LBD. The Western blot confirmed that the protein is AR, in comparison with Figure 2B .
Determining the affinity of the AR-LBD protein chip for FITC-T
The fluorescent intensity indicates the amount of FITC-T bound to the protein arrays. The specific binding was enhanced with the increase of FITC-T doses and reached saturation at the concentration of 10 nM. From a Scatchard analysis of the specific binding RFUs, the K d of AR protein arrays for FITC-T was 0.61 nM.
Determining the competitive ability of MT with FITC-T using the converse AR-LBD protein chip strategy
The competition profile is shown in Figure 4 . The original result was presented by a gray-scale map (Fig. 4A) . It was inverted to show the inhibition ability of MT with testosterone ( Fig. 4B) . Spot intensities, which symbolized the degree of inhibition in this assay, increased with the increasing MT concentrations. We got a sigmoid dose-dependent curve that indicated the MT competitive binding (Fig. 4C) . The IC 50 value of MT was 2.88 nM. 
Evaluating the reliability of the method
The gray-scale map (Fig. 5A) was converted to a rainbow figure also. The signal (Fig. 5B) of the 0.1% DMSO control group showed no obvious difference compared with that of the negative group. The signals of a, b and the positive groups with MT evidently increased compared with that of the negative control group. The effects of a, b groups can be discriminated by their different RFUs. The Z′ factor was 0.76, which can meet the requirement of model reliability (>0.4), and the CV% was 0.358%.
High-throughput compound screening by the converse AR-LBD chip
In total, 10,067 compounds from our center collection were initially screened. A representative result of 1 block from the HTS is shown in Figure 6A rainbow map, we can clearly see the positive control in the first and last 3 spots and also notice the negative control in the upper right-hand and lower left-hand sides. Seven active compounds were selected from this block. In total, 190 compounds with inhibitory activity >60% were identified in the primary screening. These candidates were further tested to calculate their IC 50 . Finally, 3 compounds had specific inhibitory potency against testosterone with IC 50 s of 3.63, 2.19, and 1.71 μM.
DISCUSSION
The AR plays a key role in the proper development and function of male reproductive organs, such as the prostate and epididymis, as well as nonreproductive organs, such as muscle, hair follicles, and brain. Abnormalities in the androgen-AR signaling pathway have been linked to diseases, including male infertility, Kennedy's disease, and prostate cancer. For decades, the AR has been a significant target of drugs, aimed at the therapy of diseases caused by altered androgen levels/responsiveness or the improvement of physical performance and regulation of male fertility. In this study, we developed the AR-LBD protein chip with a novel strategy to screen the AR agonists and antagonists.
In this work, the soluble fusion proteins encoding AR-LBD segments were expressed in E. coli using the pET32a expression vector. 21 Because the AR-LBD is highly conserved and has biological characteristics with similarities between rats and humans (~97%), 22 we used rat AR cDNA as a template to prepare the AR-LBD protein. Following the extraction of mRNA from the rat ventral prostate, we prepared the AR-LBD cDNA by RT-PCR. The plasmid pET-32a/AR was constructed and transformed into E. coli strains BL21 for expression. Large quantities of AR-LBD proteins were produced in soluble form with a molecular weight of 54.4 kDa.
Receptor proteins must be immobilized in a native conformation to maintain their biological function. 23 After having tested many current surfaces of the protein chip, such as bissulfosuccinimidyl suberate, dimethyl suberimidate, polylysine, and so on, the silane-polysaccharide surface showed the best biological compatibility. This surface was used successfully in multireceptor immobilization, including estrogen receptor-β, adrenergic receptor-β 2 , μ-opioid receptor, androgen receptor, and so forth, in prohibited drug detection. 15 To verify the receptor binding activity on the chip, we performed the traditional ligand binding saturation assay and a competitive assay using different strategies. As shown in Figure 3 , the shape of the dose dependence curve showed a typical convex curve, which suggested a positive cooperative binding of labeled testosterone with the protein arrays. After the Scatchard analysis, the K d of testosterone is 0.61 nM, consistent with the literature (0.49 nM). 24 From the converse competitive assays, the "S" curve also suggested a positive competition on the AR-LBD chip (Fig. 5) . The affinity of compounds for the AR-LBD chip can be determined by measuring its ability to compete with, and thus inhibit, the binding of FITC-T. The IC 50 of MT is 2.88 nM, consistent with the literature From the evaluation assay of the methodology (Fig. 4) , this method has a good sensitivity and reliability. Z′ factor and CV% (coefficient of variance) are usually used to evaluate the HTS method. The Z′ factor and CV% of this model were 0.76 (>0.4) and 0.358%, respectively, confirming the method's reliability. The compounds with various binding potencies can be separated efficiently by the chip. A good sensitivity of tests is also shown in Figure 4 . There was still an obvious difference of RFUs between 0.1 and 0.01 nM MT. Because compounds were dissolved in 0.1% DMSO, we tried to figure out the effect of DMSO on the protein chip. Based on the results, 0.1% DMSO does not affect the binding assay on the chip (Fig. 5) . The converse strategy makes the compound's HTS of the protein chip applicable and effective. The unbound fluorescent ligands can be easily moved from the chip surface. The whole reaction time is about 30 min.
We are aware of the current limitations of this method. First, like traditional receptor ligand binding assays, the AR-LBD chip cannot distinguish agonists from antagonists of AR. However, this work can be achieved by other biological assays.
Second, the false-positive appearance occurred in the primary screening. This was caused by the various physiochemical properties of compounds, such as fluorescence bleach, sticky property, and so on. This issue can be solved by a secondary screen with an IC 50 calculation.
In summary, the AR-LBD protein chip with the novel strategy is an attempt to improve the screening efficiency and avoid radiation hazard. This applied assay could prospectively be extended to detect other biological compounds. 
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